Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Docetaxel Plus Cisplatin

Docetaxel Plus Cisplatin Am J Cancer 2003; 2 (5): 357-358 GUEST COMMENTARIES 1175-6357/03/0005-0357/$30.00/0 © Adis Data Information BV 2003. All rights reserved. two docetaxel arms compared with the control arm. Thus, both docetaxel-cisplatin and docetaxel-carboplatin now become rea- A Viewpoint by Chandra Belani and Sakkaraiappan Ramalingam sonable options for the firstline treatment of patients with ad- University of Pittsburgh School of Medicine, vanced or metastatic NSCLC. University of Pittsburgh Cancer Institute, Pittsburgh, The docetaxel-platinum regimens have widened the therapeu- PA, USA tic options for the treatment of advanced NSCLC. The above data The treatment of advanced NSCLC has evolved over the past also provide a compelling argument for the evaluation of the few years. Platinum-based two-drug combination chemotherapy, docetaxel-cisplatin regimen in particular, both as adjuvant treat- considered as the ‘standard of care’, results in modest improve- ment of resected disease and as induction for potentially resectable ments in both survival and quality of life. The use of the docetaxel/ NSCLC. Strategies to predict response to docetaxel, platinum cisplatin combination for the treatment of chemotherapy-naive compounds and other active agents are currently being pursued, in patients with advanced NSCLC has been evaluated in randomized an attempt to individualize therapy based on patient characteris- http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Docetaxel Plus Cisplatin

Abstract

Am J Cancer 2003; 2 (5): 357-358 GUEST COMMENTARIES 1175-6357/03/0005-0357/$30.00/0 © Adis Data Information BV 2003. All rights reserved. two docetaxel arms compared with the control arm. Thus, both docetaxel-cisplatin and docetaxel-carboplatin now become rea- A Viewpoint by Chandra Belani and Sakkaraiappan Ramalingam sonable options for the firstline treatment of patients with ad- University of Pittsburgh School of Medicine, vanced or metastatic NSCLC. University of Pittsburgh Cancer...
Loading next page...
 
/lp/springer-journals/docetaxel-plus-cisplatin-MdzlNZ108J
Publisher
Springer Journals
Copyright
Copyright © 2003 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200302050-00006
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2003; 2 (5): 357-358 GUEST COMMENTARIES 1175-6357/03/0005-0357/$30.00/0 © Adis Data Information BV 2003. All rights reserved. two docetaxel arms compared with the control arm. Thus, both docetaxel-cisplatin and docetaxel-carboplatin now become rea- A Viewpoint by Chandra Belani and Sakkaraiappan Ramalingam sonable options for the firstline treatment of patients with ad- University of Pittsburgh School of Medicine, vanced or metastatic NSCLC. University of Pittsburgh Cancer Institute, Pittsburgh, The docetaxel-platinum regimens have widened the therapeu- PA, USA tic options for the treatment of advanced NSCLC. The above data The treatment of advanced NSCLC has evolved over the past also provide a compelling argument for the evaluation of the few years. Platinum-based two-drug combination chemotherapy, docetaxel-cisplatin regimen in particular, both as adjuvant treat- considered as the ‘standard of care’, results in modest improve- ment of resected disease and as induction for potentially resectable ments in both survival and quality of life. The use of the docetaxel/ NSCLC. Strategies to predict response to docetaxel, platinum cisplatin combination for the treatment of chemotherapy-naive compounds and other active agents are currently being pursued, in patients with advanced NSCLC has been evaluated in randomized an attempt to individualize therapy based on patient characteris-

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.